A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

Start Date20 Jun 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT05494697 / RecruitingPhase 2

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

Start Date01 May 2024

Sponsor / Collaborator

AIM ImmunoTech, Inc.

[+1]

NCT05756166 / RecruitingPhase 1/2IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

Start Date16 Feb 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Rintatolimod

100 Translational Medicine associated with Rintatolimod

100 Patents (Medical) associated with Rintatolimod

Literatures (Medical) associated with Rintatolimod

01 Nov 2023·Journal for immunotherapy of cancer

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Article

Author: Kokolus, Kathleen M ; Wallace, Paul K ; Attwood, Kristopher ; Grimm, Melissa J ; Slomba, Ronald T ; Witkiewicz, Agnieszka ; O'Connor, Tracey L ; Minderman, Hans ; Williams, Lauren ; Groman, Adrienne ; Levine, Ellis G ; Kalinski, Pawel ; Soh, Kah Teong ; Early, Amy P ; Maguire, Orla ; Opyrchal, Mateusz ; Gandhi, Shipra ; Tarquini, Mary Lynne

Background:

Presence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts the effectiveness of cancer immunotherapies. The ability of toll-like receptor 3 (TLR3) ligands, interferons (IFNs) and COX2 inhibitors to synergistically induce CTL-attracting chemokines (but not regulatory T cell (Treg)-attractants) in the TME, but not in healthy tissues, observed in our preclinical studies, suggested that their systemic application can reprogram local TMEs.

Methods:

Six evaluable patients (33–69 years) with metastatic triple-negative breast cancer received six doses of systemic chemokine-modulating (CKM) regimen composed of TLR3 ligand (rintatolimod; 200 mg; intravenous), IFN-α2b (20 MU/m2; intravenous) and COX2 inhibitor (celecoxib; 2×200 mg; oral) over 2 weeks. The predetermined primary endpoint was the intratumoral change in the expression of CTL marker, CD8α, in the post-CKM versus pre-CKM tumor biopsies. Patients received follow-up pembrolizumab (200 mg, intravenously, every 3 weeks), starting 3–8 days after completion of CKM.

Results:

Post-CKM biopsies showed selectively increased CTL markers CD8α (average 10.2-fold, median 5.5-fold, p=0.034) and granzyme B (GZMB; 6.1-fold, median 5.8-fold, p=0.02), but not FOXP3 (Treg marker) relative to HPRT1 expression, resulting in the increases in average CD8α/FOXP3 ratio and GZMB/FOXP3 ratio. CKM increased intratumoral CTL-attractants CCL5 and CXCL10, but not Treg-attractants CCL22 or CXCL12. In contrast, CD8+T cells and their CXCR3+subset showed transient decreases in blood. One clinical response (breast tumor autoamputation) and three stable diseases were observed. The patient with clinical response remains disease free, with a follow-up of 46 months as of data cut-off.

Conclusions:

Short-term systemic CKM selectively increases CTL numbers and CTL/Treg ratios in the TME, while transiently decreasing CTL numbers in the blood. Transient effects of CKM suggest that its simultaneous application with checkpoint blockade and other forms of immunotherapy may be needed for optimal outcomes.

01 Apr 2023·Antiviral research

Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action

Article

Author: Daino, Gian Luca ; Strayer, David ; Mitchell, William M ; Distinto, Simona ; Tramontano, Enzo ; Paulis, Annalaura ; Corona, Angela

Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status. 100% protection from lethal EBOV-Zaire in Balb/c mice was achieved by rintatolimod (Ampligen) at the well tolerated human clinical dose of 6 mg/kg. The data indicate that the mechanism of action is rintatolimod's dual ability to act as both a competitive decoy for the IID domain of VP35 blocking viral dsRNA sequestration and as a pathogen-associated molecular pattern (PAMP) restricted agonist for direct TLR3 activation but lacking RIG-1-like cytosolic helicase agonist properties. These data show promise for rintatolimod as a prophylactic therapy against human Ebola outbreaks.

01 Jan 2023·American journal of cancer research

Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3.

Article

Author: van den Bosch, Thierry Pp ; Hofland, Leo J ; van Eijck, Casper Hj ; van Koetsveld, Peter M ; van Eijck, Casper Wf ; Doukas, Michail ; Haddaoui, Hassana El ; Mustafa, Dana Am

Pancreatic cancer has a dismal prognosis, and treatment options for patients with locally advanced or metastatic disease are limited. Early tumor progression after standard chemo- and or radiotherapy remains a major concern in managing these patients. Treating pancreatic cancer patients with the Toll-like receptor 3 (TLR-3) agonist rintatolimod (Ampligen^®) was effective in boosting the immune response. Rintatolimod acts via the TLR-3 receptor on several immune cells. However, the TLR-3 expression pattern in pancreatic cancer cells and how rintatolimod affects pancreatic cancer cells have not yet been investigated. The TLR-3 protein and mRNA expression were evaluated in thirteen PDAC tissue samples as well as in the human PDAC (hPDAC) cell lines CFPAC-1, MIAPaCa-2, and PANC-1 using immunohistochemistry and multiplexed gene expression analysis, respectively. The direct anti-tumor effects of rintatolimod were investigated using a proliferation and migration assay after different incubation time points with increasing concentrations of rintatolimod (ranging from 0.05 to 0.4 mg/ml). The TLR-3 protein and mRNA expression were heterogeneous between the PDAC tissue samples and the three hPDAC cell lines. TLR-3 protein and mRNA expression were high in CFPAC-1, moderate in MIAPaCa-2, and undetectable in PANC-1. Rintatolimod three-day treatment resulted in significantly reduced proliferation of CFPAC-1 cells compared to vehicle-treated control cells. In addition, after 24 hours, rintatolimod-treated CFPAC-1 cells showed less cell migration compared to vehicle-treated control cells, although this difference was not statistically significant. Lastly, we identified fifteen genes, altered with a Log₂ FOC > |1.0| in rintatolimod-treated CFPAC-1 cells, which were significantly related to three transcription factors (NFKB1, RELA, and SP1) regulating the TLR-3 signaling pathway. In conclusion, we propose that rintatolimod treatment might have a direct TLR-3-dependent anti-tumoral effect on pancreatic cancer cells expressing TLR-3.

107

News (Medical) associated with Rintatolimod

10 Jun 2024

·www.globenewswire.com

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024 at 1:00 PM ET. As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Immunotherapy

31 May 2024

·www.biospace.com

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregistered Class B warrants to purchase up to an aggregate of 5,640,958 shares of common stock. The Class A and Class B warrants will each have an exercise price of $0.363, will be exercisable six months from the date of issuance and, in the case of the Class A warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class B warrants, will expire on the five-year anniversary from the initial exercise date. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $2.0 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company. Maxim Group LLC is acting as the sole placement agent in connection with the offering. The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 4, 2022. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, at (212) 895-3745. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, the warrants and the shares of common stock underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com

16 May 2024

·www.biospace.com

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below). “AIM is making fundamental progress across our clinical development programs and continues to be encouraged by Ampligen’s potential. We recently reported encouraging top-line data across our pipeline. We also recently completed cGMP manufacturing of 9,000 vials of Ampligen. Both of these successes are extremely important as we seek commercial partners. We remain focused on the continued execution of our operational, clinical and regulatory initiatives and seek to generate — through such progress — a basis for increased stockholder value,” commented AIM Chief Executive Officer Thomas K. Equels. Recent Highlights Completed cGMP manufacturing of clinical vials of Ampligen Announced first dose level is generally well-tolerated in Phase 1b/2 study of Ampligen and Imfinzi as a combination therapy for late-stage pancreatic cancer Announced appointment of Charles Lapp, MD as a Consulting Medical Officer for AIM’s ME/CFS and Long COVID programs Reported positive top-line, protocol-planned interim report data from the study of Ampligen combined with pembrolizumab for the treatment of recurrent ovarian cancer: In the ongoing, investigator-initiated Phase 2, single-arm efficacy/safety trial, University of Pittsburgh Medical Center researchers saw an Objective Response Rate of 45% when combining Ampligen, pembrolizumab and cisplatin in platinum-sensitive subjects with recurrent ovarian cancer. Objective Response Rate includes complete response and partial response to treatment. There was a total Clinical Benefit Rate of 55% when including patients who experienced stable disease. Researchers also reported a median Progression-Free Survival of 7.8 months. Released multiple CEO Corner segments highlighting Company news and clinical programs Expected Upcoming Pipeline Milestones Q2 2024 Final dataset for Post-COVID Conditions (AMP-518) 2024 Locally Advanced Pancreatic Adenocarcinoma (AMP-270) – First Subject Dosed Publications of data in scientific journals Summary of Financial Highlights for First Quarter 2024 As of March 31, 2024, AIM reported cash, cash equivalents and marketable securities of $10.9 million. Research and development expenses for the three months ended March 31, 2024, were $2.0 million, compared to $2.1 million for the same period in 2023. General and administrative expenses were $3.8 million for the three months ended March 31, 2024, compared to $2.3 million for the same period 2023. The net loss from operations for the three months March 31, 2024, was $5.8 million, or $0.12 per share, compared to $3.7 million, or $0.08 per share, for the three months ended March 31, 2023. Please refer to the full 10-Q for complete details. Conference Call and Webcast Details As previously announced, the Company will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results today, May 16, 2024 at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com, and will be archived for 90 days following the live event. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com

Financial StatementPhase 2Executive ChangeClinical Result

100 Deals associated with Rintatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D09661	Rintatolimod	L03A	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fatigue Syndrome, Chronic	AR	AIM ImmunoTech, Inc.	01 Jan 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Melanoma	Phase 2	US	National Cancer Institute	20 Jun 2024
Locally Advanced Pancreatic Adenocarcinoma	Phase 2	US	AIM ImmunoTech, Inc.	01 May 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	NL	AIM ImmunoTech, Inc.	09 Jan 2024
Secondary malignant neoplasm of pancreas	Phase 2	NL	AIM ImmunoTech, Inc.	09 Jan 2024
Post Acute COVID 19 Syndrome	Phase 2	US	AIM ImmunoTech, Inc.	30 Jun 2023
Colorectal Cancer, Hereditary Nonpolyposis, Type 1	Phase 2	US	Merck Sharp & Dohme Corp.	01 Feb 2022
Metastatic Colorectal Carcinoma	Phase 2	US	Merck Sharp & Dohme Corp.	01 Feb 2022
Refractory Colorectal Carcinoma	Phase 2	US	Merck Sharp & Dohme Corp.	01 Feb 2022
Turcot Syndrome	Phase 2	US	Merck Sharp & Dohme Corp.	01 Feb 2022
Unresectable Colorectal Carcinoma	Phase 2	US	Merck Sharp & Dohme Corp.	01 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05494697 (Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma, ASCO2024)	Phase 2	Locally Advanced Pancreatic Adenocarcinoma Maintenance	90	Rintatolimod	xskvlkmkpz(gfxghpnllc) = npsjkstpik kkhougmruf (wnndctajyj ) View more	Positive	24 May 2024
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Ampligen	kedtdmbcpi(rybtemmsfa) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. eutadvsfie (gvfokjeche ) View more	Positive	08 Feb 2024
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Placebo		Positive	08 Feb 2024
NCT03734692 (GlobeNewswire) Manual	Phase 2	Recurrent ovarian cancer	-	Ampligen+pembrolizumab	iedsxgsvlx(lmcvunxhnv) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors dcgirupozc (petvdqfjxe )	Positive	08 Nov 2023
NCT04081389 (CTgov)	Phase 1	Triple Negative Breast Cancer \| Early Stage Breast Carcinoma	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	bnnshtwxbx(cwcrdvxwne) = xnbjhudhzp tezdkihejr (vsbnxhemeo, mnjkhiszbo - ircbtcojiq) View more	-	11 Sep 2023
NCT04081389 (CTgov)	Phase 1		9	Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	bnnshtwxbx(cwcrdvxwne) = xlwnkmwatm tezdkihejr (vsbnxhemeo, fcyetvkbmn - mwavhxjscc) View more	-	11 Sep 2023
Corporate Publications Manual	Phase 1	-	40	Rintatolimod	rspfpylteu(ztlwttccgd) = awdifplpzk qopvhbrsrt (vexrxazeqk )	Positive	08 Dec 2022
Corporate Publications Manual	Phase 1	-	40	Placebo	rspfpylteu(ztlwttccgd) = lfwxefatyz qopvhbrsrt (vexrxazeqk )	Positive	08 Dec 2022
NCT04081389 (SITC2022) Manual	Phase 1	Triple Negative Breast Cancer ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	jbiqrfeprc(tkifehwaxp) = cuxvloakod zhnqtlscxv (enkjdhkyck ) View more	Positive	01 Nov 2022
NCT00215813 (AMP-511, Biospace) Manual	Not Applicable	Post Acute COVID 19 Syndrome	4	Rintatolimod	jlqoxoxlcs(bnztdemhuu) = The preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen bqtzjabqkz (hpdceaoinr )	Positive	28 Jul 2022
NCT03403634 (AACR2022) Manual	Phase 2	Colorectal Liver Metastases Microsatellite Stable (MSS)	12	celecoxib+IFNα2b IV+rintatolimod	kvfsflsxct(qwdswhztqf) = increased pgajooxxhk (nvuvavapvj ) Met View more	Positive	15 Jun 2022
NCT03599453 (AACR2022)	Early Phase 1	Metastatic Triple-Negative Breast Carcinoma	6	Systemic rintatolimod and interferon-α2b	zkitvakefw(jmryoddmic) = fhzdotgjwb npfqyjlpjf (gdgjamiqzd ) View more	-	15 Jun 2022
NCT03599453 (GlobeNewswire) Manual	Phase 1	Metastatic Triple-Negative Breast Carcinoma Triple Negative	6	IFN-2+Celecoxib+Ampligen+Pembrolizumab	wmffvexsfw(ivzbsbfsru) = ddjcsgyttj dnerdtqqna (vexksvffzh ) View more	Positive	11 Apr 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis